Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Border to Coast Pensions Partnership Ltd

Border to Coast Pensions Partnership Ltd increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 338,358 shares of the medical equipment provider's stock after acquiring an additional 42,753 shares during the quarter. Border to Coast Pensions Partnership Ltd owned approximately 0.17% of Zimmer Biomet worth $38,295,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. Kingswood Wealth Advisors LLC boosted its holdings in Zimmer Biomet by 20.0% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider's stock valued at $295,000 after purchasing an additional 435 shares during the last quarter. Stifel Financial Corp raised its position in shares of Zimmer Biomet by 10.8% during the 4th quarter. Stifel Financial Corp now owns 96,032 shares of the medical equipment provider's stock valued at $10,144,000 after buying an additional 9,341 shares during the period. Proficio Capital Partners LLC acquired a new position in Zimmer Biomet in the fourth quarter valued at approximately $55,000. QRG Capital Management Inc. grew its position in Zimmer Biomet by 13.9% in the first quarter. QRG Capital Management Inc. now owns 6,775 shares of the medical equipment provider's stock worth $767,000 after acquiring an additional 827 shares during the period. Finally, State of Alaska Department of Revenue increased its stake in Zimmer Biomet by 2.7% during the first quarter. State of Alaska Department of Revenue now owns 23,316 shares of the medical equipment provider's stock worth $2,638,000 after acquiring an additional 620 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider now directly owns 20,424 shares of the company's stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.39% of the company's stock.

Zimmer Biomet Stock Down 0.9%

Shares of NYSE:ZBH opened at $91.93 on Friday. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $116.71. The stock has a market cap of $18.19 billion, a price-to-earnings ratio of 20.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.72. The firm's 50 day moving average price is $94.77 and its 200 day moving average price is $102.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The company's revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.94 earnings per share. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.04%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's payout ratio is currently 21.24%.

Analysts Set New Price Targets

Several equities analysts have recently commented on ZBH shares. JMP Securities decreased their price target on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley decreased their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Wells Fargo & Company dropped their price target on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, Raymond James Financial dropped their target price on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and a consensus target price of $111.53.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.